实用肝脏病杂志2015，Vol.18Issue(3)：312-316,5.DOI:10.3969/j.issn.1672-5069.2015.02.029
乙型肝炎病毒阿德福韦酯耐药相关变异的研究进展
Research progress of drug-resistant mutations associated with adefovir dipivoxil of hepatitis B virus
摘要
Abstract
Adefovir dipivoxil (ADV),an oral nucleotide analogue,remains as one of the major antiviral agents in the treat-ment of chronic hepatitis B(CHB) in China. However,long-term therapy with ADV may lead to hepatitis B virus(HBV) drug-re-sistant mutations. The signature mutations associated with ADV resistance are rtA181V and rtN236T. The newly-identified ADV primary resistant mutations are rtA181S,rtE218G and rtN236V. In addition,some other mutations including rtA181T,rtV214A, rtQ215H/P/S,rtL217R/P,rtI233V,and rtN238T/D/H remain contradictory,and these mutations need to be further identified.关键词
乙型肝炎病毒/阿德福韦酯/耐药/基因变异/抗病毒治疗Key words
hepatitis B virus/Adefovir dipivoxil/Drug resistance/Gene mutation/Antiviral therapy引用本文复制引用
叶晓玲,刘妍..乙型肝炎病毒阿德福韦酯耐药相关变异的研究进展[J].实用肝脏病杂志,2015,18(3):312-316,5.基金项目
北京市然科学基金面上项目(7132224),国家自然科学基金面上项目(81371852) （7132224）
